Generic Medicine Info
Should be taken with food. Swallow whole, do not chew/crush. For patients w/ swallowing difficulties, disperse tab thoroughly in a glass of water & drink immediately. Rinse the glass w/ water several times & drink each rinse completely.
Hypersensitivity to etravirine. Severe hepatic (Child-Pugh Class C) impairment. Lactation.
Special Precautions
Patient w/ hepatitis B or C. Not indicated for use in treatment-naive patients. Mild to moderate hepatic impairment. Pregnancy. Monitoring Parameters Monitor viral load, CD4 count, cholesterol, triglycerides, hepatic transaminases (if signs or symptoms of hypersensitivity develops), signs and symptoms of infection and skin rash.
Adverse Reactions
Significant: Fat redistribution (e.g. Cushingoid appearance, central obesity, buffalo hump, peripheral and facial wasting, breast enlargement), immune reconstitution syndrome, osteonecrosis, mild to moderate rash. Nervous: Fatigue, headache, peripheral neuropathy, malaise, drowsiness. CV: MI, angina pectoris, HTN. GI: Nausea, abdominal pain, diarrhoea, flatulence, gastritis, GERD, dry mouth, vomiting, pancreatitis. Resp: Bronchospasm. Hepatic: Hepatitis, increased liver enzymes. Genitourinary: Renal failure. Endocrine: DM, hyperglycaemia, hyperlipidaemia. Haematologic: Anaemia. Musculosckeletal: Rhabdomyolysis, myopathy. Ophthalmologic: Blurred vision. Dermatologic: Sweating.
Potentially Fatal: Rarely, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, drug rash w/ eosinophilia and systemic symptoms (DRESS), hepatic failure.
Drug Interactions
May decrease plasma concentrations and therapeutic effects of indinavir, antiarrhythmics (e.g. amiodarone, quinidine, flecainide, systemic lidocaine, disopyramide, mexiletine, propafenone), itraconazole, ketoconazole, lovastatin, rosuvastatin, simvastatin, immunosuppressants (e.g. ciclosporin, sirolimus, tacrolimus). May increase plasma concentrations of warfarin, diazepam, digoxin. Decreased plasma concentrations w/ carbamazepine, phenobarbital, phenytoin, rifampicin, rifapentine, dexamethasone. May inhibit metabolism of clopidogrel.
CIMS Class
ATC Classification
J05AG04 - etravirine ; Belongs to the class of non-nucleoside reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on etravirine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in